Title : ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.

Pub. Date : 2015 Jan

PMID : 25375038






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib erb-b2 receptor tyrosine kinase 2 Mus musculus
2 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib erb-b2 receptor tyrosine kinase 2 Mus musculus
3 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib erb-b2 receptor tyrosine kinase 2 Mus musculus